Zhitong Finance App News, Chuangsheng Group Pharmaceutical-B (06628) issued an announcement. Since the Company and the Company's current auditor, Ernst & Young (EY), failed to reach an agreement on the audit fees for the annual audit of the Group's consolidated financial statements (2026 audit) for the year ended December 31, 2026, the Group's operating scale was drastically reduced after considering the sale of CDMO assets in the second half of 2026.

On the recommendation of the Board of Directors Audit Committee, the Company proposed to dismiss Ernst & Young as the Company's auditor for the year ended December 31, 2026 (recommended dismissal), and to appoint Guowei Certified Public Accountants Limited (Guowei) as the Company's new auditor for the year ended December 31, 2026 to fill the temporary vacancy after the proposed dismissal. The term of office is until the end of the next Annual General Meeting of Shareholders of the Company.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.